Strong demand for Botox, generating $1.49 billion in quarterly revenue, persists despite intense competition. AbbVie's 2024 earnings per share forecast falls in the range of $11.05 - $11.25 billion, aligning with analyst estimates at the upper end of this range, specifically at $11.24. #AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

The negative outlook stemming from CVS Health's decision to delist Humira poses a challenge, but AbbVie aims to counter the lost revenue with new immunology products Skyrizi and Rinvoq. In its 2027 projection, AbbVie raised the revenue forecast for these drugs from $21 billion to $27 billion.#AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

AbbVie reported robust financial results, with earnings reaching $2.79 per share and revenue totaling $14.3 billion. This surpassed market expectations of $2.77 per share and $14.01 billion in revenue. Despite increased competition impacting Humira, one of the company's leading drugs, leading to a 41% YoY decline in Q4 sales to $3.30 billion, it still exceeded analyst estimates of $3.28 billion. #AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #2024Projection